ARS Pharmaceuticals, Inc. (SPRY)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY). Investors who purchased ARS securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether ARS has violated federal securities laws.
On September 19, 2023, the FDA rejected the epinephrine nasal spray developed by ARS. The FDA’s complete response letter (CRL) also requested additional efficacy and safety. Following this news, ARS stock dropped roughly 55% during intraday trading on September 20, 2023.
If you are aware of any facts relating to this investigation or purchased ARS securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | [email protected]